Novara Mark David 4

What Happened
Novara Mark David, EVP & Chief Commercial Officer of Tandem Diabetes Care (TNDM), sold 2 shares in an open‑market transaction on March 5, 2026 at $22.81 per share, for a total of $46. This was a sale (not a purchase), and the size of the transaction is very small.

Key Details

• Transaction date: March 5, 2026; filing date: March 9, 2026 (Form 4).
• Price and quantity: 2 shares at $22.81 each; total proceeds $46.
• Shares owned after the transaction: Not reported in the provided excerpt.
• Footnote: Sale executed pursuant to a Rule 10b5‑1 trading plan adopted by the reporting person on December 4, 2025.
• Timeliness: Filed March 9, 2026 for a March 5 transaction (within the Form 4 reporting period).

Context
A 10b5‑1 plan allows insiders to sell shares according to a prearranged schedule and is commonly used to avoid questions about timing; it does not necessarily indicate a change in the insider’s view of the company. Because the sale amount is de minimis ($46), it is unlikely to be material to investors.